# 🚯 EDISON

# **AFT Pharmaceuticals**

A licensing deal for Pascomer

AFT Pharmaceuticals has reported a North American licensing deal for Pascomer, a topical formulation of rapamycin being developed for facial angiofibromas in tuberous sclerosis complex (TSC), to private US-based Timber Pharmaceuticals. Timber will fund clinical development and provide AFT with over US\$10m in upfront, development and regulatory milestones, as well as over US\$10m in sales milestone payments and royalties. An Investigational New Drug Application has been approved by the FDA. The first of two 120-patient clinical studies is expected to start shortly, with results in 2020.

Year end	Revenue (NZ\$m)	PBT* (NZ\$m)	EPS* (NZ\$)	DPS (NZ\$)	P/E (x)	Yield (%)
03/18	81.2	(12.9)	(0.13)	0.0	N/A	N/A
03/19	85.1	(2.5)	(0.03)	0.0	N/A	N/A
03/20e	99.9	6.4	0.07	0.0	45.6	N/A
03/21e	119.5	17.6	0.18	0.0	17.7	N/A

Note: \*PBT and EPS are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments.

## An attractive orphan market

According to the US National Institute of Neurological Disorders and Stroke, TSC affects between 25,000 and 40,000 Americans and one to two million people worldwide. Angiofibromas, which can be highly disfiguring, affect around 80% of patients with TSC. Current therapies are typically surgical, such as chemical peeling, excision and laser surgery.

# Evidence of rapamycin efficacy

Oral rapamycin was first approved in 1999 for immunosuppressant use. Initial evidence of its potential efficacy in angiofibromas occurred in a patient who initiated oral rapamycin because of renal transplantation and her facial angiofibromas improve markedly. A review of recent studies indicates that compounded topical formulations of rapamycin have improved lesions in 94% of subjects although there is no topical formulation available commercially.

# A low-risk development plan for AFT

The licensing agreement with Timber allows AFT to retain some of the upside potential of Pascomer but without having to yield near- to medium-term profitability to fund its development. Timber will have full responsibility for R&D investment, while AFT will collect high-margin royalties if Pascomer is successfully developed.

## Valuation: NZ\$495m or NZ\$5.09 per share

We are maintaining our valuation of NZ\$495m or NZ\$5.09 per share. To be conservative, we are not including Pascomer development in our estimates due to its early stage but we will revisit this as the programme progresses. Also, the company reiterated its operating profit target is between NZ\$9m and NZ\$12m for FY20.


## Development update

Pharma & biotech

## 10 July 2019

Price	NZ\$3.19
Market cap	NZ\$310m
	NZ\$0.65/US\$
Net debt (NZ\$m) at 31 March 2019	34.8
Shares in issue	97.3m
Free float	21.6%
Code	AFT
Primary exchange	NZX
Secondary exchange	ASX

## Share price performance



### **Business description**

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company's product portfolio includes prescription and over-the-counter drugs to treat a range of conditions and a proprietary nebuliser.

### Next events

Additional Maxigesic launches	2019
Analysts	
Maxim Jacobs	+1 646 653 7027
Nathaniel Calloway	+1 646 653 7036
healthcare@edisongroup.com	

#### Edison profile page

AFT Pharmaceuticals is a research client of Edison Investment Research Limited



# Pascomer for facial angiofibromas in TSC

AFT has announced it has licensed Pascomer, which is being developed for facial angiofibromas in TSC patients, to Timber Pharmaceuticals for over US\$10m in upfront, development and regulatory milestones, as well as over US\$10m in sales milestone payments and royalties.

TSC is a multisystem, autosomal dominant genetic disorder resulting from a mutation in one of two tumour suppressor genes, TSC1 (encoding hamartin) or TSC2 (tuberin). TSC is characterised by benign tumours, known as hamartomas, in various organs, most commonly the skin, brain, kidneys, heart and lungs. A hamartoma is composed of an overgrowth of mature cells and tissues, which normally occurs in the affected tissue. TSC affects both sexes and all ethnic groups, affecting as many as 25,000–40,000 individuals in the US and one to two million individuals worldwide, with an estimated prevalence of one in 6,000 newborns according to the US National Institute of Neurological Disorders and Stroke. Angiofibromas, which can be highly disfiguring, affect around 80% of patients with TSC.

Pascomer is a topical version of rapamycin (marketed as Rapamune by Pfizer), an immunosuppressant used for prophylaxis of organ rejection in patients receiving kidney transplants. It is also approved for the treatment of lymphangioleiomyomatosis, a progressive disease often associated with TSC that results in lung destruction. Rapamycin is an inhibitor of mammalian target of rapamycin (mTOR), which has many functions in protein synthesis and cell growth and is aberrantly activated in patients with TSC, making it a logical target for development in the treatment of this disease.

Initial evidence of rapamycin's potential efficacy in angiofibromas occurred in a patient who initiated oral rapamycin because of renal transplantation and her facial angiofibromas improve markedly.<sup>1</sup> As rapamycin is a potent immunosuppressive, systemic exposure for the sake of improving facial angiofibromas is not ideal and there have been several small studies of topical rapamycin in this indication.

According to one review, 94% of the 84 patients treated with a topical rapamycin in various studies showed improvement in their lesions.<sup>2</sup> In the one randomised, double-blind, placebo-controlled study (with 23 subjects) in the review, 73% of the subjects who received treatment reported a subjective improvement in their angiofibromas compared to 38% in placebo although the p value was not significant (p=0.18), likely because of the size of the study.<sup>3</sup> Importantly, although a variety of different topical formulations were used, rapamycin was detected in only three patients out of the 74 tested for serum rapamycin levels, indicating a lack of systemic exposure. However, one of the issues with the various topical formulations used in these studies is that stability is limited. AFT believes it has developed a formulation using a proprietary dermal delivery technology that would be stable and hence commercially viable.

For intellectual property, there are no unexpired patents related to Rapamune in the FDA Orange Book so AFT appears to be free to operate. We do not know the extent of the patent estate for Pascomer but at the very least it will be eligible for orphan drug exclusivity, which is seven years in

<sup>1</sup> Hofbauer et al. The mTOR inhibitor rapamycin significantly improves facial angiofibroma lesions in a patient with tuberous sclerosis. *British Journal of Dermatology* 2008 159, pp. 473–475

<sup>2</sup> Balestri et al., Analysis of current data on the use of topical rapamycin in the treatment of facial angiofibroma in Tuberous Sclerosis Complex. *Journal of the European Academy of Dermatology and Venereology.* 2015, 29, 14–20

<sup>3</sup> Koenig et al. Topical rapamycin therapy to alleviate the cutaneous manifestations of tuberous sclerosis complex. *Drugs in R&D* 2012 Sep: 12(3): 121–126



the United States and 10 years' worth of data exclusivity in the EU (although we would expect patent coverage to go well beyond that due to the proprietary nature of the formulation).

As part of the agreement, Timber will cover the clinical trial costs associated with clinical development. An Investigational New Drug Application has already been approved by the FDA with the first of two 120-patient clinical studies expected to start shortly in eight centres in the US (the Mayo Clinic), Australia, New Zealand, Spain and the UK. Results are expected in 2020.

## Valuation

We are maintaining our valuation of NZ\$495m or NZ\$5.09 per share as Pascomer development is too early stage to include in our estimates. We will revisit this as the programme progresses.

	Terminal EBIT margin					
Terminal revenue growth	30.00%	34.00%	36.0%	40.0%	45.0%	
-2%	3.42	3.71	3.85	4.14	4.50	
-1%	3.60	3.92	4.08	4.39	4.79	
0%	3.83	4.17	4.35	4.69	5.13	
1%	4.10	4.48	4.68	5.06	5.54	
2%	4.44	4.87	5.09	5.52	6.06	
3%	4.87	5.37	5.62	6.11	6.73	
4%	5.45	6.03	6.32	6.90	7.62	
5%	6.27	6.96	7.30	8.00	8.86	

Exhibit 1: DCF sensitivity table (NZ\$/share)

Source: Edison Investment Research

# **Financials**

We are maintaining our financial estimates as the precise size of the upfront payment is undisclosed. Also, the company has reiterated its operating profit target of between NZ\$9m and NZ\$12m for FY20.



## Exhibit 2: Financial summary

NZ\$000	2018	2019	2020e	2021e
March	NZ GAAP	NZ GAAP	NZ GAAP	NZ GAAF
PROFIT & LOSS				
Revenue	81,176	85,127	99,947	119,505
Cost of Sales	(45,880)	(44,397)	(51,547)	(56,407)
Gross Profit	35,296	40,730	48,400	63,098
EBITDA	(10,479)	5,797	10,288	21,447
Operating Profit (before amort. and except.)	(10,353)	5,912	10,403	21,562
Intangible Amortisation	214	204	204	204
Exceptionals	0	0	0	0
Other	(364)	1,716	1,802	1,892
Operating Profit	(10,503)	7,832	12,409	23,658
Net Interest	(2,527)	(8,375)	(4,000)	(4,000)
Profit Before Tax (norm)	(12,880)	(2,463)	6,403	17,562
Profit Before Tax (reported)	(12,666)	(2,259)	8,409	19,658
Tax	(12,000)	(168)	0,405	000
Profit After Tax (norm)	(12,938)	(2,631)	6,403	17,562
Profit After Tax (reported)	(12,724)		8,409	19,658
	· · · /	(2,427)		
Average Number of Shares Outstanding (m)	97.2	97.3	97.3	97.3
EPS - normalised (NZ\$)	(0.13)	(0.03)	0.07	0.18
EPS - (reported) (NZ\$)	(0.14)	(0.03)	0.09	0.20
Dividend per share (c)	0.00	0.00	0.00	0.00
Gross Margin (%)	43.5	47.8	48.4	52.8
EBITDA Margin (%)	N/A	6.8	10.3	17.9
Operating Margin (16)	N/A	6.9	10.4	18.0
	14// \	0.0	10.4	10.0
BALANCE SHEET				
Fixed Assets	8,291	12,334	15,540	18,785
Intangible Assets	5,118	8,239	11,245	14,366
Tangible Assets	330	357	557	681
nvestments	2,843	3,738	3,738	3,738
Current Assets	48,312	51,261	53,543	69,382
Stocks	24,412	25,158	27,958	30,594
Debtors	16,954	19,187	17,474	19,121
Cash	6,946	6,916	8,112	19,667
Other	0	0	0	0
Current Liabilities	(18,607)	(58,504)	(15,249)	(16,567)
Creditors	(18,489)	(16,368)	(15,249)	(16,567)
Short term borrowings	0	(41,750)	0	0
Long Term Liabilities	(30,654)	0	(41,750)	(41,750)
Long term borrowings	(30,654)	0	(41,750)	(41,750)
Other long term liabilities	0	0	0	0
Net Assets	7,342	5,091	12,084	29,850
CASH FLOW		.,	1	
	(6 592)	0.610	0 701	10 100
Operating Cash Flow	(6,582)	9,610	8,721	19,120
Net Interest	(4,264)	(8,375)	(4,000)	(4,000)
Tax	(58)	(168)	0	0 50 0
Capex	(2,853)	(3,465)	(3,525)	(3,564)
Acquisitions/disposals	(3,002)	(1,419)	0	C
Financing	877	0	0	0
Dividends	(412)	(134)	0	C
Net Cash Flow	(16,294)	(3,951)	1,196	11,556
Dpening net debt/(cash)	7,446	23,708	34,834	33,638
HP finance leases initiated	0	0	0	0
Other	32	(7,175)	(0)	0
Closing net debt/(cash)	23,708	34,834	33,638	22,083

Source: Edison Investment Research, company accounts



#### General disclaimer and copyright

This report has been commissioned by AFT Pharmaceuticals and prepared and issued by Edison, in consideration of a fee payable by AFT Pharmaceuticals. Edison Investment Research standard fees are £49,500 pa for the production and broad dissemination of a detailed note (Outlook) following by regular (typically quarterly) update notes. Fees are paid upfront in cash without recourse. Edison may seek additional fees for the provision of roadshows and related IR services for the client but does not get remunerated for any investment banking services. We never take payment in stock, options or warrants for any of our services.

Accuracy of content: All information used in the publication of this report has been compiled from publicly available sources that are believed to be reliable, however we do not guarantee the accuracy or completeness of this report and have not sought for this information to be independently verified. Opinions contained in this report represent those of the research department of Edison at the time of publication. Forward-looking information or statements in this report contain information that is based on assumptions, forecasts of future results, estimates of amounts not yet determinable, and therefore involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of their subject matter to be materially different from current expectations.

Exclusion of Liability: To the fullest extent allowed by law, Edison shall not be liable for any direct, indirect or consequential losses, loss of profits, damages, costs or expenses incurred or suffered by you arising out or in connection with the access to, use of or reliance on any information contained on this note.

No personalised advice: The information that we provide should not be construed in any manner whatsoever as, personalised advice. Also, the information provided by us should not be construed by any subscriber or prospective subscriber as Edison's solicitation to effect, or attempt to effect, any transaction in a security. The securities described in the report may not be eligible for sale in all jurisdictions or to certain categories of investors.

Investment in securities mentioned: Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison Group does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison's policies on personal dealing and conflicts of interest.

Copyright: Copyright 2019 Edison Investment Research Limited (Edison). All rights reserved FTSE International Limited ("FTSE") © FTSE 2019. "FTSE®" is a trade mark of the London Stock Exchange Group companies and is used by FTSE International Limited under license. All rights in the FTSE indices and/or FTSE ratings vest in FTSE and/or its licensors. Neither FTSE nor its licensors accept any liability for any errors or omissions in the FTSE indices and/or FTSE ratings or underlying data. No further distribution of FTSE Data is permitted without FTSE's express written consent.

#### **Australia**

Edison Investment Research Pty Ltd (Edison AU) is the Australian subsidiary of Edison. Edison AU is a Corporate Authorised Representative (1252501) of Crown Wealth Group Pty Ltd who holds an Australian Financial Services Licence (Number: 494274). This research is issued in Australia by Edison AU and any access to it, is intended only for "wholesale clients" within the meaning of the Corporations Act 2001 of Australia. Any advice given by Edison AU is general advice only and does not take into account your personal circumstances, needs or objectives. You should, before acting on this advice, consider the appropriateness of the advice, having regard to your objectives, financial situation and needs. If our advice relates to the acquisition, or possible acquisition, of a particular financial product you should read any relevant Product Disclosure Statement or like instrument.

#### **New Zealand**

The research in this document is intended for New Zealand resident professional financial advisers or brokers (for use in their roles as financial advisers or brokers) and habitual investors who are "wholesale clients" for the purpose of the Financial Advisers Act 2008 (FAA) (as described in sections 5(c) (1)(a), (b) and (c) of the FAA). This is not a solicitation or inducement to buy, sell, subscribe, or underwrite any securities mentioned or in the topic of this document. For the purpose of the FAA, the content of this report is of a general nature, is intended as a source of general information only and is not intended to constitute a recommendation or opinion in relation to acquiring or disposing (including refraining from acquiring or disposing) of securities. The distribution of this document is not a "personalised service" and, to the extent that it contains any financial advice, is intended only as a "class service" provided by Edison within the meaning of the FAA (i.e. without taking into account the particular financial situation or goals of any person). As such, it should not be relied upon in making an investment decision.

#### **United Kingdom**

This document is prepared and provided by Edison for information purposes only and should not be construed as an offer or solicitation for investment in any securities mentioned or in the topic of this document. A marketing communication under FCA Rules, this document has not been prepared in accordance with the legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing ahead of the dissemination of investment research.

This Communication is being distributed in the United Kingdom and is directed only at (i) persons having professional experience in matters relating to investments, i.e. investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "FPO") (ii) high net-worth companies, unincorporated associations or other bodies within the meaning of Article 49 of the FPO and (iii) persons to whom it is otherwise lawful to distribute it. The investment or investment or whot his document relates is available only to such persons. It is not intended that this document be distributed or passed on, directly or indirectly, to any other class of persons and in any event and under no circumstances should persons of any other description rely on act upon the contents of this document.

This Communication is being supplied to you solely for your information and may not be reproduced by, further distributed to or published in whole or in part by, any other person.

#### **United States**

The Investment Research is a publication distributed in the United States by Edison Investment Research, Inc. Edison Investment Research, Inc. is registered as an investment adviser with the Securities and Exchange Commission. Edison relies upon the "publishers' exclusion" from the definition of investment adviser under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws. This report is a bona fide publication of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. As such, Edison does not offer or provide personal advice and the research provided is for informational purposes only. No mention of a particular security, portfolio of securities, ransaction or investment strategy is suitable for any specific person.

Frankfurt +49 (0)69 78 8076 960 Schumannstrasse 34b 60325 Frankfurt Germany London +44 (0)20 3077 5700 280 High Holborn London, WC1V 7EE United Kingdom New York +1 646 653 7026 1,185 Avenue of the Americas 3rd Floor, New York, NY 10036 United States of America Sydney +61 (0)2 8249 8342 Level 4, Office 1205 95 Pitt Street, Sydney NSW 2000, Australia

5